These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24977458)

  • 1. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review.
    Corbelli J; Shaikh N; Wessel C; Hess R
    Menopause; 2015 Jan; 22(1):114-21. PubMed ID: 24977458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women.
    Archer DF; Schmelter T; Schaefers M; Gerlinger C; Gude K
    Menopause; 2014 Mar; 21(3):227-35. PubMed ID: 23963307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review.
    Nelson HD
    JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy.
    Lantto H; Haapalahti P; Tuomikoski P; Viitasalo M; Väänänen H; Sovijärvi AR; Ylikorkala O; Mikkola TS
    Menopause; 2012 Jan; 19(1):82-8. PubMed ID: 21934534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.
    Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C
    Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
    Archer DF; Pickar JH; MacAllister DC; Warren MP
    Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
    Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
    Haines C; Yu SL; Hiemeyer F; Schaefers M
    Climacteric; 2009 Oct; 12(5):419-26. PubMed ID: 19479489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Continuous Transdermal Nitroglycerin for Treating Hot Flashes by Inducing Nitrate Cross-tolerance in Perimenopausal and Postmenopausal Women: A Randomized Clinical Trial.
    Huang AJ; Cummings SR; Ganz P; Schembri M; Raghunathan H; Vittinghoff E; Gibson CJ; Grady D
    JAMA Intern Med; 2023 Aug; 183(8):776-783. PubMed ID: 37273224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.
    Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB; Lambrecht LJ
    Menopause; 2009; 16(1):132-40. PubMed ID: 18971794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
    Archer DF;
    Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women.
    Rozenbaum H; Chevallier O; Moyal M; Durand G; Perineau M; This P;
    Climacteric; 2002 Sep; 5(3):249-58. PubMed ID: 12419083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H
    Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.
    Pinkerton JV; Constantine G; Hwang E; Cheng RF;
    Menopause; 2013 Jan; 20(1):28-37. PubMed ID: 23010882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis.
    Derzko C; Sergerie M; Siliman G; Alberton M; Thorlund K
    Menopause; 2016 Mar; 23(3):294-303. PubMed ID: 26382309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.